Form 8-K

8-K — WW INTERNATIONAL, INC.

Accession: 0001193125-26-210279

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0000105319

SIC: 7200 (SERVICES-PERSONAL SERVICES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d116881d8k.htm (Primary)

EX-99.1 (d116881dex991.htm)

EX-99.2 (d116881dex992.htm)

GRAPHIC (g116881dsp017.jpg)

GRAPHIC (g116881dsp018.jpg)

GRAPHIC (g116881dsp019.jpg)

GRAPHIC (g116881dsp020.jpg)

GRAPHIC (g116881dsp021.jpg)

GRAPHIC (g116881dsp022.jpg)

GRAPHIC (g116881dsp023.jpg)

GRAPHIC (g116881dsp024.jpg)

GRAPHIC (g116881dsp025.jpg)

GRAPHIC (g116881dsp026.jpg)

GRAPHIC (g116881dsp027.jpg)

GRAPHIC (g116881dsp028.jpg)

GRAPHIC (g116881dsp029.jpg)

GRAPHIC (g116881dsp030.jpg)

GRAPHIC (g116881dsp031.jpg)

GRAPHIC (g116881dsp032.jpg)

GRAPHIC (g116881dsp033.jpg)

GRAPHIC (g116881dsp034.jpg)

GRAPHIC (g116881dsp035.jpg)

GRAPHIC (g116881dsp036.jpg)

GRAPHIC (g116881dsp037.jpg)

GRAPHIC (g116881dsp038.jpg)

GRAPHIC (g116881dsp039.jpg)

GRAPHIC (g116881dsp040.jpg)

GRAPHIC (g116881dsp041.jpg)

GRAPHIC (g116881dsp042.jpg)

GRAPHIC (g116881dsp043.jpg)

GRAPHIC (g116881dsp044.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d116881d8k.htm · Sequence: 1

8-K

false 0000105319 0000105319 2026-05-07 2026-05-07 0000105319 stpr:VA 2026-05-07 2026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 7, 2026

WW INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Virginia

001-16769

11-6040273

(State or other jurisdiction

of incorporation)

(Commission File

Number)

(IRS Employer

Identification No.)

18 West 18th Street, 7th Floor, New York, New York

10011

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (212) 589-2700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, no par value

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 7, 2026, WW International, Inc. issued a press release and a Shareholder Letter announcing its financial results for its fiscal quarter ended March 31, 2026. Copies of the press release and the Shareholder Letter are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including the text of the press release attached as Exhibit 99.1 and the Shareholder Letter attached as Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained in Items 2.02 and 9.01 of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document or filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Description

Exhibit 99.1

Press Release dated May 7, 2026.

Exhibit 99.2

Shareholder Letter dated May 7, 2026.

Exhibit 104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WW INTERNATIONAL, INC.

DATED: May 7, 2026

By:

/s/ Felicia DellaFortuna

Name:

Felicia DellaFortuna

Title:

Chief Financial Officer

EX-99.1

Filename: d116881dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Weight Watchers Announces First Quarter 2026 Results

Total End of Period Subscribers of 2.7 million; End of Period Clinical Subscribers of 197 thousand, up 46% year-over-year

Revenue of $168 million; Clinical Subscription Revenue of $39 million, up 32% year-over-year

Reaffirms Full Year 2026 Financial Guidance

Announces Fully Subscribed Debt Prepayment Solicitation as Part of Actions Expected to Reduce Debt by $42 Million

NEW YORK (May 7, 2026) – WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in

science-backed weight management, today announced its results for the first quarter of fiscal 2026 ended March 31, 20261 in this Earnings Press Release and a Shareholder Letter issued today

and posted on the Company’s Corporate Website.

“We remain confident in our strategy to build the industry-leading weight health platform. Our focus

is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made

encouraging progress in Q1, with End of Period Clinical Subscribers growing 51% sequentially, and Core+, our higher value Behavioral tier that includes expert support and community experiences, returning to year-over-year growth.”

“We are pleased with our Q1 results. Adjusted Gross Margin2 remains near record highs as we continue to

drive operational efficiencies across our portfolio of businesses,” said Felicia DellaFortuna, Chief Financial Officer and member of the Company’s Interim Office of the Chief Executive. “We are reaffirming our 2026 Revenue and

Adjusted EBITDA2 guidance and expect Adjusted EBITDA2 and cash generation to increase in the remaining quarters of 2026. Our strengthened

capital structure, including the recently announced debt prepayment actions, position us to execute on our transformation while maintaining financial discipline.”

Q1 Business Updates

●

Q1 2026 Clinical Subscription Revenue grew 32% year-over-year and End of Period Clinical Subscribers grew 46%

year-over-year, despite lapping significant prior year growth in Q1 2025 from the Company’s former compounded semaglutide offering.

●

Core+ represented 537 thousand of End of Period Subscribers at the end of Q1 2026, which increased 6% from

505 thousand End of Period Subscribers at the end of Q1 2025.

●

Q1 Monthly Subscription Revenue Per Average Subscriber (ARPU) increased 13% year-over-year, reflecting a continued mix

shift towards the Company’s higher ARPU Med+ and Core+ membership tiers. This mix shift partially offset secular headwinds in the Company’s Core membership tier that drove a 10% decrease in Revenue year-over-year.

●

Q1 Gross Margin was 70.5%. Q1 Adjusted Gross Margin2 was 73.6%,

which remained near record highs, despite an accelerating mix shift towards Clinical, as margin profiles improved through structural actions and operational efficiencies.

●

Q1 Net Loss was $52.0 million, which reflects higher depreciation and amortization related to Fresh Start Accounting1. Q1 Adjusted EBITDA2 was a loss of $1.8 million reflecting marketing investment in peak season.

Balance Sheet and Liquidity Updates

●

Cash and Cash Equivalents balance as of March 31, 2026 was $121 million.

●

In Q2 2026, the Company expects to pay $37 million in cash to prepay and reduce the principal amount of its

outstanding term loan. The prepayment will be comprised of the following two components:

○

In June 2026, $27 million in aggregate principal amount of prepayment from the annual cash sweep; and

○

In May 2026, $10 million as part of the previously announced voluntary solicitation, which was fully subscribed at

68.5% of par.

The Company expects these actions to reduce the aggregate principal amount of its outstanding term loan by

$42 million, utilizing $37 million of cash, and to reduce its annualized interest expense by approximately $4 million3.

Fiscal 2026 Guidance

The Company reaffirms previously provided

full year fiscal 2026 guidance.

●

Revenue guidance of $620 million to $635 million.

●

Adjusted EBITDA2 guidance of $105 million to $115 million.

First Quarter 2026 Conference Call and Webcast

The Company has scheduled a conference call today at 8:30 a.m. ET to discuss results. The webcast of the conference call will be available on the Company’s

corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

1Fresh Start Accounting and Predecessor and Successor Periods

In connection with the Company’s

emergence from its financial reorganization process on June 24, 2025, the Company applied fresh start accounting which resulted in Successor and Predecessor financial statement presentation. References to “Successor” relate to the

Company’s operations for the three months ended March 31, 2026 and the period from June 25, 2025 through December 31, 2025. References to “Predecessor” relate to the Company’s operations for the three months

ended March 29, 2025. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or prior to that date.

2Statement regarding Non-GAAP Financial Measures

To supplement the Company’s consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”),

the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. The Company presents in this release non-GAAP financial

measures, including earnings before interest, taxes, depreciation and amortization expenses and

share-based compensation expense (“EBITDA”); and for each period presented, EBITDA adjusted, as applicable, for (a) goodwill and other intangible assets impairments,

(b) reorganization items, net related to the Company’s emergence from its Chapter 11 financial reorganization, (c) transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization,

(d) net restructuring charges associated with the previously disclosed 2025, 2024, and 2023 restructuring plans, (e) non-CEO executive separation expenses and (f) other items such as the impact

of foreign exchange gains and losses as indicated in the reconciliations below that management believes are not indicative of ongoing operations (“Adjusted EBITDA”). The Company also presents gross profit, gross margin, marketing

expenses, selling, general and administrative expenses, and product development expenses on a non-GAAP basis that adjusts for similar items, as further indicated in the reconciliations below.

As exchange rates are an important factor in understanding period-to-period

comparisons, the Company believes in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand the Company’s operating results and evaluate the

Company’s performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company uses results on a constant currency basis as one

measure to evaluate the Company’s performance. In this press release, the Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. The Company generally refers to such amounts

calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance

with GAAP and are not meant to be considered in isolation. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented

in accordance with GAAP.

Management believes these non-GAAP financial measures provide useful supplemental information to

investors regarding the performance of the Company’s business and are useful for period-over-period comparisons of the performance of the Company’s business. While the Company believes that these

non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a

substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

See “Reconciliation of Non-GAAP Financial Measures” in this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the

non-GAAP financial measures to the most directly comparable GAAP measures.

A reconciliation of the forward-looking full

year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such

reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a

material impact on its future GAAP financial results.

3The interest rate in effect for the term loan

as of March 31, 2026 was 10.51%.

Definitions

“Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to add on unlimited access

to the Company’s workshops.

“Clinical” business refers to providing subscriptions to the Company’s clinical product offerings

provided by Weight Watchers Clinic combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops.

“Revenue”—“Subscription Revenue” consists of the aggregate of: (a) “Behavioral Subscription Revenue”, the fees

associated with subscriptions for the Company’s Behavioral offerings; and (b) “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. In addition, “Other

Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

“Incoming Subscribers”—“Subscribers” refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill

programs in Company-owned operations. The “Incoming Subscribers” metric reports Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric

to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“End of Period

Subscribers”—The “End of Period Subscribers” metric reports Subscribers in Company-owned operations at a given period end. Recruitment and retention are key drivers for this metric. Management utilizes this metric to

monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“Monthly Subscription Revenue Per Average

Subscriber” (“ARPU”) — The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average

Subscriber for its businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each respective business are calculated as Subscription

Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each

respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for

year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for

each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis.

About Weight Watchers

Weight Watchers is the global leader in

science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60

years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based

clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members

the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded

with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is

rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This news release includes “forward-looking statements,” within the meaning of Section 27A of

the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiatives, and prospects. The

Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim”

and similar expressions in this news release to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ

materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: the Company’s recent emergence from bankruptcy, which could

adversely affect its business and relationships and subjects us to risks and uncertainties; competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived

weight management methods; the Company’s failure to continue to retain and grow its subscriber base; the Company’s ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss

market; the Company’s ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to

successfully expand into new channels of distribution or respond to consumer trends or sentiment; the Company’s ability to successfully implement strategic initiatives; the effectiveness and efficiency of its advertising and marketing

programs, including the strength of its social media presence; the impact on the Company’s reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other

partners; the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company’s workforce; the Company’s chief executive officer transition,

and its ability to appoint a new chief executive officer with the required level of experience and expertise in a timely manner; the Company’s ability to successfully make acquisitions or enter into collaborations or joint ventures, including

its ability to successfully integrate, operate or realize the anticipated benefits of such businesses; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary

environment, changes in tariffs and escalating trade tensions, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company’s

business; the Company’s failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by us of

leases; the inability to renew certain of the Company’s licenses, or the inability to do so on terms that are favorable to us; the dependence of the Company’s payments system on third-party service providers; the impact of the

Company’s exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company’s debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the

Company’s technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company’s ability to successfully

integrate and use artificial intelligence in its business; the Company’s ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual

property rights; the impact of existing and future laws and regulations; risks related to the Company’s exposure to extensive and complex healthcare laws and regulations; the outcomes of litigation or regulatory actions; risks and

uncertainties associated with the Company’s international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the

Company’s ability to engage in share repurchases and pay cash dividends in the foreseeable future; risks related to the actions of activist shareholders and anti-takeover provisions in the Company’s articles of incorporation and bylaws;

risks related to the actions of the Company’s shareholders and the exclusive forum provisions in its articles of incorporation; the possibility that the Company could fail to maintain the listing of the Company’s common stock on Nasdaq;

and other risks and uncertainties,

including those included in this press release and those detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission (the

“SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many

important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any

obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are

advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:

John Mills or Anna Kate Heller

WeightWatchers@icrinc.com

For media inquiries, please contact:

Lizzy Levitan

WW@hunt-gather.com

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

UNAUDITED

Successor

March 31, 2026

December 31, 2025

ASSETS

CURRENT ASSETS

Cash and cash equivalents

120,870

160,279

Restricted cash

5,797

6,298

Receivables (net of allowances: March 31, 2026 - $1,935 and December 31, 2025 -

$1,651)

16,856

16,378

Prepaid income taxes

3,325

8,097

Prepaid marketing and advertising

5,150

9,275

Prepaid expenses and other current assets

16,347

13,277

TOTAL CURRENT ASSETS

168,345

213,604

Property and equipment, net

7,485

8,115

Operating lease assets

2,549

2,933

Goodwill

200,000

200,135

Other intangible assets, net

471,528

490,664

Deferred income taxes

16,254

16,482

Other noncurrent assets

14,910

14,825

TOTAL ASSETS

881,071

946,758

LIABILITIES AND EQUITY

CURRENT LIABILITIES

Portion of long-term debt due within one year, net

26,808

—

Portion of operating lease liabilities due within one year

1,183

1,260

Accounts payable

17,077

9,212

Salaries and wages payable

20,364

34,375

Accrued marketing and advertising

15,875

22,985

Accrued interest

1,086

1,084

Other accrued liabilities

21,641

23,049

Income taxes payable

10,311

6,006

Deferred revenue

26,749

28,565

TOTAL CURRENT LIABILITIES

141,094

126,536

Long-term debt, net

438,632

465,466

Long-term operating lease liabilities

1,571

1,893

Deferred income taxes

33,705

34,021

Other noncurrent liabilities

498

771

TOTAL LIABILITIES

615,500

628,687

EQUITY

Successor common stock, $0 par value; 1,000,000 shares authorized; 9.996 shares issued at

March 31, 2026 and 9,992 shares issued at December 31, 2025

379,306

378,777

Accumulated deficit

(114,095

)

(62,095

)

Accumulated other comprehensive income

360

1,389

TOTAL EQUITY

265,571

318,071

TOTAL LIABILITIES AND TOTAL EQUITY

881,071

946,758

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

UNAUDITED

Successor

Predecessor

Three Months Ended

March 31, 2026

Three Months Ended

March 29, 2025

Subscription revenue, net (1)

167,357

185,180

Other revenue, net (2)

904

1,391

Revenue, net

168,261

186,571

Cost of subscription revenue (3)

49,445

53,587

Cost of other revenue

144

108

Cost of revenue

49,589

53,695

Gross profit

118,672

132,876

Marketing expenses

92,934

78,778

Product development expenses

8,093

11,121

Selling, general and administrative expenses

48,084

35,629

Franchise rights acquired impairments

—

27,549

Operating loss

(30,439

)

(20,201

)

Interest expense

11,475

27,603

Other (income) expense, net

(737

)

2,206

Loss before income taxes

(41,177

)

(50,010

)

Provision for income taxes

10,823

22,575

Net loss

(52,000

)

(72,585

)

Net loss per share

Basic

(5.20

)

(0.91

)

Diluted

(5.20

)

(0.91

)

Weighted average common shares outstanding

Basic

9,996

80,129

Diluted

9,996

80,129

Note: Totals may not sum due to rounding.

(1) “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s

Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.

(2) “Other revenue, net” consists of revenue from licensing, franchise fees with respect to

commitment plans and royalties, publishing and other revenue.

(3) “Cost of subscription

revenue” consists of cost of revenue and operating expenses for the Company’s Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

UNAUDITED

Successor

Predecessor

Three Months Ended

March 31, 2026

Three Months Ended

March 29, 2025

Operating activities:

Net loss

(52,000

)

(72,585

)

Adjustments to reconcile net loss to cash (used for) provided by operating activities:

Depreciation and amortization

25,886

6,914

Amortization of deferred financing costs and debt (premium) discount, net

(26

)

1,254

Impairment of franchise rights acquired

—

27,549

Impairment of intangible and long-lived assets

Share-based compensation expense

391

860

Deferred tax benefit

(312

)

(2,529

)

Allowance for doubtful accounts

100

Foreign currency exchange rate (gain) loss

(738

)

2,238

Changes in cash due to:

Receivables

(688

)

761

Prepaid expenses

5,835

5,946

Accounts payable

7,556

19,435

Accrued liabilities

(21,854

)

8,785

Deferred revenue

(1,722

)

(154

)

Other long term assets and liabilities, net

(302

)

(107

)

Income taxes

4,324

16,453

Cash (used for) provided by operating activities

(33,547

)

14,998

Investing activities:

Capital expenditures

—

)

Capitalized software and website development expenditures

(5,797

)

(3,170

)

Cash used for investing activities

(5,797

)

(3,175

)

Financing activities:

Borrowings on revolving credit facility

—

171,341

Taxes paid related to net share settlement of equity awards

—

(93

)

Cash provided by financing activities

—

171,248

Effect of exchange rate changes on cash and cash equivalents and restricted cash

(566

)

1,529

Net (decrease) increase in cash and cash equivalents and restricted cash

(39,910

)

184,600

Cash and cash equivalents and restricted cash, beginning of period

166,577

56,520

Cash and cash equivalents and restricted cash, end of period

126,667

241,120

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

Variance

Successor

Predecessor

2026

Three Months Ended

2026

Constant Currency

March 31, 2026

March 29, 2025

GAAP

Constant Currency

GAAP

2025

Selected Financial Data

Revenue (1)

168,261

164,007

186,571

(9.8%)

(12.1%)

Behavioral Subscription Revenue (2)

128,524

124,317

155,723

(17.5%)

(20.2%)

Clinical Subscription Revenue (3)

38,833

29,457

31.8%

Subscription Revenue (4)

167,357

163,150

185,180

(9.6%)

(11.9%)

Other Revenue (5)

904

858

1,391

(35.0%)

(38.3%)

Note: Totals may not sum due to rounding.

(1) “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

(2) “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.

(3) “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the

Company’s Clinical offerings.

(4) “Subscription Revenue” is the sum of Behavioral

Subscription Revenue and Clinical Subscription Revenue.

(5) “Other Revenue” consists of

revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

OPERATIONAL STATISTICS

(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)

UNAUDITED

Successor

Predecessor

Three Months Ended

March 31, 2026

March 29, 2025

Variance

(Constant Currency)

Incoming Subscribers

(1)

Incoming Behavioral Subscribers

2,631

N/A

3,244

(18.9%)

N/A

Incoming Clinical Subscribers

130

N/A

41.9%

N/A

Incoming Subscribers

2,761

N/A

3,336

(17.2%)

N/A

End of Period Subscribers

(2)

End of Period Behavioral Subscribers

2,463

N/A

3,299

(25.4%)

N/A

End of Period Clinical Subscribers

197

N/A

135

45.9%

N/A

End of Period Subscribers

2,659

N/A

3,434

(22.6%)

N/A

Monthly Subscription Revenue Per Average Subscriber (3)

Monthly Behavioral Subscription Revenue Per Average Subscriber

16.82

16.27

15.87

6.0%

2.6%

Monthly Clinical Subscription Revenue Per Average Subscriber

79.23

86.70

(8.6%)

Monthly Subscription Revenue Per Average Subscriber

20.59

20.07

18.24

12.9%

10.0%

Note: Totals may not sum due to rounding.

(1) The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.

(2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations

at a given period end.

(3) The “Monthly Subscription Revenue Per Average Subscriber”

metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as

Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers

for the respective quarterly period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

Successor

Predecessor

Three Months Ended

March 31, 2026

March 29, 2025

Selling,

Product

General, and

Product

General, and

Gross

Marketing

Development

Administrative

Gross

Marketing

Development

Administrative

Profit

Expenses

Profit

Expenses

GAAP

118,672

92,934

8,093

48,084

132,876

78,778

11,121

35,629

% of Revenue

70.5%

55.2%

4.8%

28.6%

71.2%

42.2%

6.0%

19.1%

Adjustments:

Transaction Costs (1)

—

(10,823

)

Depreciation and Amortization Expenses

5,180

—

(20,706

)

4,500

—

(61

)

(2,354

)

Restructuring Charges (2)

(65

)

—

(533

)

(384

)

—

(1,356

)

Share-based Compensation Expense

(141

)

(109

)

(436

)

—

(860

)

Non-CEO Executive Separation Expenses (3)

—

(1,563

)

—

Total Adjustments

5,115

(141

)

(109

)

(23,238

)

4,116

—

(61

)

(15,394

)

Adjusted

123,787

92,793

7,984

24,846

136,992

78,778

11,060

20,235

% of Revenue

73.6%

55.1%

4.7%

14.8%

73.4%

42.2%

5.9%

10.8%

Currency Adjustment

(3,690

)

(959

)

—

(301

)

N/A

Constant Currency

114,982

91,975

8,093

47,783

N/A

% of Revenue

70.1%

56.1%

4.9%

29.1%

N/A

Adjusted Constant Currency

120,097

91,834

7,984

24,546

N/A

% of Revenue

73.2%

56.0%

4.9%

15.0%

N/A

Note: Totals may not sum due to rounding.

(1) Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

(2) Restructuring charges consist of expenses associated with the reduction in headcount as a result of

certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring

plan.

(3) Certain non-recurring expenses in connection with

the separation from the Company of a non-Chief Executive Officer executive.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

Successor

Predecessor

Three Months Ended

March 31, 2026

March 29, 2025

Net Loss

(52,000

)

(72,585

)

Net Loss Margin

(30.9%

)

(38.9%

)

Interest

11,475

27,603

Taxes

10,823

22,575

Depreciation and Amortization Expenses

25,886

6,914

Share-based Compensation Expense

686

860

EBITDA

(3,130

)

(14,633

)

EBITDA Margin

(1.9%

)

(7.8%

)

Franchise Rights Acquired Impairments

(1)

—

27,549

Transaction Costs (2)

—

10,823

Restructuring Charges (3)

468

972

Non-CEO Executive Separation Expenses (4)

1,563

—

Other (5)

(737

)

2,206

Adjusted EBITDA

(1,836

)

26,917

Adjusted EBITDA Margin

(1.1%

)

14.4%

Note: Totals may not sum due to rounding.

(1) The Company’s franchise rights acquired impairment charge related to its United States unit of account.

(2) Certain non-recurring transaction costs related to strategic

alternatives and the Company’s Chapter 11 financial reorganization.

(3) Restructuring charges

consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously

disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.

(4) Certain non-recurring expenses in connection with the separation from the Company of a non-Chief Executive Officer executive.

(5) Primarily consists of the impact of foreign exchange gains and losses.

EX-99.2

Filename: d116881dex992.htm · Sequence: 3

EX-99.2

Exhibit 99.2

Business Update Building Integrated Weight Health Platform: Continuing to execute on our strategy to provide industry-leading weight

health care, which we expect to drive superior member health outcomes and lifetime value. Profitable Clinical Growth: Q1 2026 Clinical Subscription Revenue grew 32% year-over-year and End of Period Clinical Subscribers grew 46% year-over-year,

despite lapping significant prior year growth in Q1 2025 from our former compounded semaglutide offering. Core+ Growth: Core+, our higher value Behavioral tier that includes expert support and community experiences, represented 537 thousand of

End of Period Subscribers at the end of Q1 2026, which increased 6% from 505 thousand End of Period Subscribers at the end of Q1 2025. Revenue: ARPU increased 13% year-over-year reflecting a continued mix shift towards our higher ARPU Med+ and

Core+ tiers. This mix shift partially offset secular headwinds in our Core tier that drove a 10% decrease in Revenue year-over-year. Gross Margin: Q1 Gross Margin was 70.5%. Q1 Adjusted Gross Margin’” was 73.6%, which remained near

record highs, despite an accelerating mix shift towards Clinical, as margin profiles have improved. Reaffirming 2026 Guidance: We are reaffirming previously provided full year Revenue guidance of $620 million—$635 million and Adjusted EBITDA

guidance of $105 million—$115 million. Liquidity Position Supports Debt Paydown: In Q2, we expect to utilize $37 million in cash to reduce the aggregate principal amount of our term loan by $42 million. The $37 million payment is made up of

$27 million from our annual cash sweep and $10 million as part of the voluntary solicitation, which was fully subscribed at 68.5% of par. Performance Indicators CHANGE Revenue rounded to the nearest whole million Q1 2026 2025 CHANGE Behavioral $129M

$156M Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K Successor Predecessor Financial Metrics 2026 Q12025 Gross Margin 70.5% 71.2% Adjusted Gross Margin 73.6% 73.4% Net (Loss) ($52.0M) ($72.6M) Net (Loss) Margin

(30.9%) (38.9%) Adjusted EBITDA ($1.8M) $26.9M Adjusted EBITDA Margin’” (1.1%) 14.4% See “Definitions and Performance Indicators” for definitions for Revenue, End of Period Subscribers and Monthly Subscription

Revenue per Average Subscriber. i. A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and

financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the

probable significance of the unavailable information, which could have a material impact on its future GAAP financial results. ii. In connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the

Company applied fresh start accounting which resulted in Successor and Predecessor financial statement 2 presentation. References to “Successor” relate to our operations for the three months ended March 31, 2026. References to

“Predecessor” relate to our operations for the three months ended March 29, 2025. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or

prior to that date. iii. See “Reconciliation to GAAP Measures of Non-GAAP Financial Measures” for further detail on adjustments to the most comparable GAAP financial measures.

To Our Valued Shareholders Last quarter’s letter laid out Weight Watchers’ strategy to continue driving superior member

outcomes and a return to growth through an integrated weight health ecosystem. We remain confident in this approach and are singularly focused on execution. Integrating groundbreaking medical advances, such as

GLP-1s, and time-tested behavioral and community programming, sets Weight Watchers apart. Our portfolio of weight health offerings-including our Points® Program, expert support, tailored medical support

programs, and access to GLP-1 medications-enables members to migrate through our ecosystem’s offerings based on their needs, driving better health outcomes and higher lifetime value. The opportunity

ahead is significant Q1 brought significant developments in the GLP-1 market with demand for GLP-1s rising even further with the launch of oral formulations. Employers,

payers, and the government are increasingly interested in driving tangible weight health benefits and economic returns. But even as adoption grows and benefits become clearer, a growing body of evidence is also illustrating that today many people

are not staying on GLP-1s long-term1-and that, absent other interventions, patients are likely to regain weight after discontinuing treatment2. Comprehensive care models and support systems like ours that go

beyond the prescription are critical to maximizing the potential of GLP-1s going forward. Weight Watchers is perfectly positioned to fill this need. For more than 60 years, we have been the global leader in

delivering behavioral frameworks and human support and accountability that enable sustainable weight health. The evidence backs our approach: at 12 months, Med+ members prescribed a GLP-1 medication who

engaged regularly with the GLP-1 Success Program lost 29.1% more body weight, on average, than those who did not engage in behavioral support3. But as our members know well, transformations require time and

discipline. We are in the early stages of a multi-year reinvention that will require a sustainable approach. That is why, as we shift our legacy business to address market realities, we are committed to finding consistent, incremental wins that

facilitate our long-term ambitions. Promising results in an evolving market Clinical End of Period Subscribers increased 51% quarter-over-quarter to 197K in Q1, with more than 20K of Q1 Clinical signups having upgraded from our current Behavioral

Subscriber base, demonstrating how our integrated weight health approach can drive higher lifetime value. Supported several new Med+ offerings: We continue to expand access to FDA approved medications, which are becoming increasingly affordable for

our members. We expanded our collaboration with Novo Nordisk to offer eligible Med+ members subscription pricing for Wegovy that reduces out-of-pocket costs. We are also

providing access to Novo Nordisk’s Wegovy and Ozempic Pills and Eli Lilly and Company’s oral GLP-1, Foundayo, through NovoCare and LillyDirect, respectively. Brand awareness continued to improve as

awareness of our GLP-1 offering increased from ~20% to ~30%, with significant room to drive additional awareness. Within our Core+ tier, member engagement in our new virtual workshop experience improved as

attendance increased year-over-year. We are continuing to strategically offer complementary virtual experiences to Core members, as those who attend a virtual experience have been 3 - 4x more likely to upgrade to Core+. In Q1, nearly 20% of Core+

signups were upgrades from Core. See “Sources” within “Sources, Definitions, and Financial Details” section for further detail on footnotes.

Solid financial foundation Our successful financial reorganization in mid 2025 has helped the Company establish and maintain a healthier

financial position that can support long-term value creation. As we continue to execute against our strategy, we remain focused on durable cash generation to further strengthen our capital structure. Gross Margin: Q1 Gross Margin was 70.5%. Q1

Adjusted Gross Margin was 73.6%, which remained near record highs as we drive operational efficiencies across our portfolio of businesses and prioritize managing the relative maturity profiles of our business lines. Reaffirming FY 2026 Guidance: We

are reaffirming our previously provided Revenue and Adjusted EBITDA” guidance, which reflects continued, but moderated, sequential growth of Clinical End of Period Subscribers, and relatively stable year-over-year declines of Behavioral End of

Period Subscribers that includes growth in Core+ Subscribers. Positive FY 2026 Cash Generation: We expect to generate cash in 2026 based on our Adjusted EBITDA” guidance and expectations for interest costs, capital expenditures, and cash tax.

Liquidity Position Supports Debt Paydown: In Q2, we expect to utilize $37 million in cash to reduce the aggregate principal amount of our term loan by $42 million. The $37 million payment is made up of $27 million from our annual cash sweep and $10

million as part of the voluntary solicitation, which was fully subscribed at 68.5% of par. Looking Ahead: A Focus on Execution As GLP-1s continue to redefine our industry, Weight Watchers has a significant opportunity to deliver better health

outcomes for millions. We strongly believe that our approach can deliver these health outcomes—and, in the process, unlock the potential for sustainable future value creation for the Company. By prioritizing high-impact initiatives to

simultaneously grow our Clinical business and stabilize our Behavioral business, we are committed to driving immediate successes that strengthen our financial footing, enhance our product, and contribute to our ultimate goal of returning the Company

to profitable long-term growth. Felicia DellaFortuna, Jon Volkmann, Chief Financial Officer Chief Operations Officer Members of the Interim Office of the Chief Executive i. See “Reconciliation to GAAP Measures of Non-GAAP Financial

Measures” for further detail on adjustments to the most comparable GAAP financial measures. ii. A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of

the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably

predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its 4 future GAAP financial results

Integrated Care Model Our weight health offerings range from digital behavioral tools to personalized coaching and medical solutions,

allowing us to meet members where they are on their weight health journey, while providing opportunities for ARPU expansion. Behavioral Tools Science-backed behavioral tools including Points® Program and tailored nutrition guidance enables

members to adopt liveable, lasting habits Community & Connection Experts, coaches, peers that provide support, accountability, and fun Tailored Programs Programming & content tailored for specific life stages and clinical areas

such as GLP-1 Success and Menopause to meet members where they are

LClinical Support, 29.1% More weight loss for Med+ members prescribed a GLP-1 H Including GLP-1 29.1%29 medication who regularly engaged

with our GLP-1 Success Program than those who did not engage5 Of Med+ participants reported the GLP-1 Success Program helped minimize side effects6 Less likely for Med+ members who met with a Registered Dietitian to discontinue their treatment plan

within the first 12 weeks compared to those who did not7 34.1% Med+ members prescribed a GLP-1 improved their diet quality by 34.7%8 Behavioral Support 7x More likely to achieve 10% weight loss Reduced calories from ultra-processed than standard

nutritional guidance9 foods10 Menopause Community Expert Human Support Advantage Support 52.5% 45% 10/5 reduction in severity of symptoms, greater weight loss by Satisfaction for in-person workshops, on average, after 1 month for members who

referred a virtual workshops, clinician visits, members on HRT11 friend, at week 1212 customer care, and dietitian sessions13

Q1 Financial Performance and 2026 Outlook

Subscribers and ARPU ARPUi growth driven by mix shift to higher value membership tiers Monthly Subscription Revenue Per Average

Subscriber (ARPU)i$18.24 $18.97 $18.52 $18.73 $20.59 +13% Y/Y Q1 2025 Combined Q3 2025 Q4 2025 Q1 2026 Q2 2025 Behavioral and Clinical ARPUi Clinical Behavioral $86.70 $78.00 $68.52 $70.82 $79.23 $15.87 $16.54 $16.39 $16.32 $16.82 Q1 2025 Combined

Q3 2025 Q4 2025 Q1 2026 Q2 2025 ARPU increased 13% year-over-year, reflecting a mix shift towards our higher-value offerings. Foreign exchange provided a $4 million benefit in the quarter, while fiscal Q1 2026 included one less day compared to

fiscal Q1 2025. Q1 Clinical ARPU was over 4x higher than Behavioral ARPU. Within the Behavioral business, Core+ has an ARPU of nearly 2x higher than Core. Q1 Clinical ARPU increased seasonally compared to Q4 as a result of significant sequential

Subscriber growth from peak season. End of Period Subscribersi (k) While Behavioral saw incremental pressure in Q1 2026, this was due in part to our strategic decision to prioritize awareness for our Med+ tier, also coinciding with the Wegovy Pill

launch. Within Behavioral, we are encouraged to see Core+ subscribers increase year-over-year from 505 thousand to 537 thousand. We are seeing members shift from Core to our Core+ and Med+ tiers, a trend that we expect to continue.

Clinical Subscribers increased 51% sequentially driven by increased awareness of our Med+ tier, strong demand for access to lower priced GLP-1 options including the new Wegovy Pill, and focused marketing

investments. End of Period Behavioral Subscribersi (k) 3,299 3,040 2,862 2,631 2,463 (16%) (19%) (20%) (19%) (25%) Q1 2025 Combined Q2 2025 Q3 2025 Q4 2025 Q1 2026 Year-over-Year End of Period Clinical Subscribersi (k) 135 127 124 130 197 55% 56%

60% 42% 46% Q1 2025 Combined Q2 2025 Q3 2025 Q4 2025 Q1 2026 Year-over-Year i. Management believes that the key performance metrics such as Subscription Revenue, Incoming and End of Period Subscribers and Monthly Subscription Revenue Per Average

Subscriber for the Successor Period when combined with the Predecessor Period provides more meaningful comparisons to other periods and are useful in identifying current business trends. Accordingly, the charts and tables in this shareholder letter

present the combined results for the three months ended June 30, 2025 as Combined 02 2025.

Revenue and Gross Margin Scaling Clinical growth while maintaining near record margin Strong Clinical performance was driven by

increasing consumer interest in medical weight loss solutions, marketing investment, and the migration of existing members from Behavioral into our Clinical business. Behavioral Revenue is seeing the benefit of Core+ in higher ARPU, while Core

remains impacted by secular and Chapter 11 financial reorganization related headwinds, in particular within our international markets. Revenue’($m) Behavioral $129M $156M Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K Q1 2025

Combined Q3 2025 Q4 2025 Q1 2026 Q2 2025 Clinical Behavioral Other Gross Margin in Q1 2026 was 70.5%. Adjusted Gross Marginii was 73.6%, which remained near record highs, despite an accelerating mix shift towards Clinical, as we’ve

significantly improved the margin profiles within both Behavioral and Clinical through structural actions and operational efficiencies. Gross Margin % of Revenue 74.9% 75.9% 75.1% 74.4% 73.4 %—73^% 73.7% 73.2% 71.2 % 72.1% 70.1%

70.5% Predecessor Predecessor Successor Successor Successor Successor Q1 2025 3/30/25- 6/25/25- Q3 2025 04 2025 Q1 2026 6/24/25 6/30/25 (ii) GAAP Gross Margin Adjusted Gross Margin i. These amounts combine the revenue of the Successor and

Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the

combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented. 9 ii. See “Reconciliation to GAAP

Measures of Non-GAAP Financial Measures” for further detail on adjustments to the most comparable GAAP financial measures.

Operating Expenses Targeted growth investment with disciplined cost management Operating Expenses Adjusted Operating Expenses’ %

of Revenue % of Revenue 8% 8% 6% Predecessor Predecessor Successor Successor Successor Successor Predecessor Predecessor Successor Successor Successor Successor Q1 2025 3/30/25- 6/25/25- Q3 2025 Q4 2025 Q1 2026 Q1 2025 3/30/25- 6/25/25- Q3 2025 Q4

2025 Q1 2026 6/24/25 6/30/25 6/24/25 6/30/25 Marketing Selling, General & Admin Product Development Marketing Selling, General & Admin Product Development Marketing expense in Q1 2026 was $93 million 1 reflecting front-loaded

investment in Q1 to drive awareness of our Med+ positioning, also coinciding with the Wegovy Pill launch. Selling, General & Administrative (SG&A) expenses were 29% of Revenue primarily driven by higher depreciation and amortization

related to Fresh Start Accounting. Adjusted SG&A was 15% of Revenue, slightly lower as a percent of Revenue than Q4 2025 reflecting the exit from our corporate headquarters lease and continued expense discipline. Product Development expense,

which primarily includes personnel costs for engineering, product, design, and data teams, was 5% of Revenue. i. See Reconciliation to GAAP Measures of Non-GAAP Financial Measures” for further detail on adjustments to the most comparable GAAP

financial measures.

Profitability Balancing strategic investment with operational discipline Q1 2026 Net Loss was $52.0 million. Adjusted EBITDA was a loss

of $1.8 million reflecting marketing investment in peak season. Net Loss also reflects higher depreciation and amortization related to Fresh Start Accounting. Structural cost actions over the last few years have solidified our financial foundation,

which allows us to fund targeted growth initiatives, while maintaining our margin profile. Net (Loss) Income ($m) and Net (Loss) Income Margin 1,191 10% (39%) (33%) (31%) 1 (6) (73) (58) (52) Predecessor

Predecessor Successor Successor Successor Successor Q1 2025 3/30/25- 6/25/25- Q3 2025 Q4 2025 Q1 2026 6/24/25 6/30/25 Net (Loss) Income ($m) ? Net (Loss) Income Margin Adjusted EBITDA(i)($m) and Adjusted EBITDA Margin(i) 34% 37% ? * 25% 14% 4

(1%) (2) Predecessor Predecessor Successor Successor Successor Successor Q1 2025 3/30/25- 6/25/25- Q3 2025 Q4 2025 Q1 2026 6/24/25 6/30/25 Adjusted EBITDA ($m) ? Adjusted EBITDA Margin i. See “Reconciliation to GAAP Measures of

Non-GAAP Financial Measures” for further detaiI on adjustments to the most comparable GAAP financial measures. 11

Cash Flow and Balance Sheet Healthy liquidity and a restructured capital base Cash ($m) Cash from Operations ($m) Behavioral $129M $156M

Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K Predecessor Successor Successor Successor Successor Predecessor Predecessor Successor Successor Successor Successor Q1 2025 6/30/25 9/30/25 12/31/25 3/31/26 Q1 2025 3/30/25- 6/25/25- Q3 2025

Q4 2025 Q1 2026 6/24/25 6/30/25 Cash and Cash Equivalents were $121 million at the end of Q1 2026, compared to $160 million at the end of Q4 2025. The sequential change primarily reflects Q1 2026 Adjusted EBITDA, quarterly interest on our Term Loan

of $12 million, capital expenditures of $6 million, and timing of marketing payments. Consistent with historical seasonality, Q1 cash from operations was a use of cash reflecting peak marketing investment. In Q2, we expect to utilize $37 million in

cash to reduce the aggregate principal amount of our term loan by $42 million. The $37 million payment is made up of $27 million from our annual cash sweep and $10 million as part of the voluntary solicitation, which was fully subscribed at 68.5% of

par. Based on the interest rate in effect for the term loan as of March 31, 2026 of 10.51%, we expect the debt paydown to reduce our annualized interest expense by approximately $4 million. Following our Q2 2025 financial reorganization, we

have fundamentally transformed our balance sheet:

2026 Outlook We are reaffirming our previously provided 2026 guidance for Revenue to be $620 million - $635 million and

Adjusted EBITDAi to be $105 million - $115 million. Revenue While we expect sequential Clinical Subscriber growth in the remaining quarters of the year, we expect sequential net adds to be lower than Q1 reflecting seasonal normalization,

lower levels of marketing spend, and a more balanced allocation of that spend. We are expecting Clinical Subscription Revenue to be approximately 25%—30% of 2026 Revenue, up from 16% of 2025 Revenue. Within our Behavioral business, we are

encouraged with the growth we are seeing within Core+ and we expect to grow Core+ subscribers in 2026. Gross Margin We remain focused on driving efficiencies within gross margin through workflow automation, technology enablement, and cost

discipline, in particular as we scale our Clinical business. While we expect modest Adjusted Gross Marginii decline in 2026 vs. 2025, we expect to remain above 72%. Operating Expense Marketing: We expect 2026 Marketing Expense as a percentage of

Revenue to increase modestly compared to 2025. Product Development: We expect to remain at a similar quarterly run-rate as Q1 2026 as we continue to execute on our multi-year technology roadmap. SG&A: We

expect modest SG&A savings in 2026, primarily driven by the exit from our corporate headquarters lease and ongoing operational discipline. Cash Generation As is typical for the business, Q1 represents our peak marketing investment period. We

expect to generate cash through the remainder of the year following first quarter cash usage. We will continue to manage liquidity and capital allocation with a focus on durable cash generation. The main drivers of Adjusted EBITDAi to our cash

generation are interest, capex, and cash tax. Interest Costs: We expect approximately $45 million - $50 million of interest costs, which reflects slightly lower quarterly interest compared to Q1 2026 following the $37 million of debt

prepayments from the cash sweep and voluntary solicitation. Capex: As we continue to invest in product innovation, technology infrastructure, and growth initiatives, we expect 2026 quarterly capital expenditures to remain at a similar run-rate as Q1 2026. Cash Taxes: We expect 2026 cash taxes to be between $5 million and $10 million. Looking Ahead As we look to the future, we continue to feel confident in our financial footing and the

immense opportunity before us. Our first quarter results demonstrate the increasing share of our growing Clinical business and Core+ tier as a percent of total End of Period Subscribers and Revenue, which supports 2026 as an important step in our

multiyear transformation i. A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and

probable significance of the unavailable information, which could have a material impact on its future GAAP financial results. ii. See “Reconciliation to GAAP Measures of Non-GAAP Financial

Measures” for further detail on adjustments to the most comparable GAAP financial measures.

First Quarter Conference Call and Webcast The Company has scheduled a conference call today at 8:30 a.m. ET to discuss results. The

webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days. About Weight Watchers Weight

Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years

of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical

interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and

sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and

one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and Live a Longer, healthier life. For more information, visit

weightwatchers.com “Weight Watchers is the only reason I’m still on a GLP-1. isn’t one-size-fits- I got nutrition, all. It fits this stage community, and of life. “ HAYLEY so much more. LESLEY Lesley, Hayley, Member PROGRESS:

-100 LB* Member -35 LB*** PROGRAM: PROGRAM: med+ menopause

Sources, Definitions and Financial Details

Sources Med+ members given the GLP-1 Companion Program lost 27 lbs, on average, after 6 months. Based on a 6-month clinical trial

(n=18O) of individuals who were enrolled between February-April 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the Med+ Program and participating in the GLP-1 Success nutrition

program. Heinberg et al. Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study. Obesity. 2025. Funded by WW International, Inc. “At 6 months, members lost on average 31.6

lbs in an observational study of Med+ member data. Ard JD, Hong YR, Foster GD, Medcalf A, Nadolsky S, Cardel Ml. Twelve-month analysis of real-world evidence from a telehealth obesity treatment provider using anti-obesity medications. Obesity. 2024.

“At 6 months, participants in a clinical trial of the WW program lost an average of 12 lbs (5.4% of body weight). Palacios et al. Effectiveness of a digital weight management program on diet quality: A randomized controlled trial. AJCN. 2025 *

At 6 months, members lost on average 31.6 lbs in an observational study of Med+ member data. Ard JD, Hong YR, Foster GD, Medcalf A, Nadolsky S, Cardel Ml. Twelve-month analysis of real-world evidence from a telehealth obesity treatment provider

using anti-obesity medications. Obesity. 2024. ***WeightWatchers members of menopausal age lost 6.8% of their body weight (14.1 lbs) in just 6 months. Based on a secondary analysis of a 6- month randomized controlled trial (n=165 women 45 years or

older with complete data) that compared participants following WW to those given standard nutritional guidelines alone. Based on a secondary analysis of a 6-month randomized controlled trial (n=165 women 45 years or older with complete data) that

compared participants following WW to those given standard nutritional guidelines alone. Funded by WW international, Inc. 1 Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years.

https://www.primetherapeutics.com/ w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years 2 Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK,

Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi:

10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252. 3 Based on an internal analysis of 3,325 members who requested at least 1 GLP-1 medication refill through Weight Watchers Med+ and selfreported both a starting weight

and weight at week 52. On average, members who logged in to the GLP-1 Success Program at least 4 days each week (n=376) lost 22.20% body weight, and members who never logged in to the app (n=2,949) lost 17.20% body weight in 52 weeks. Not a

randomized, controlled clinical trial. Self-reported outcomes have not been independently verified. Individual results may vary. 4 Based on an internal analysis of 3,260 Weight Watchers Med+ members prescribed a GLP-1 medication and self-reported

both a starting weight and a weight at month 12. On average members lost 21.0% of body weight in 12 months. Compared to an analysis of (i) 17,475 Calibrate members who received at least one month of GLP-1 medication, were enrolled and had a

valid weight at month 12, and lost 15.7% body weight in 12 months; (ii) an analysis of 500+ Form Health patients who received intensive lifestyle therapy and semaglutide, and had an average weight loss 13.6% body weight in 12 months; and

(iii) an analysis of 1,812 Hims & Hers members prescribed a compounded injectable GLP-1 medication through the Hims & Hers platform, reported their weight at month 12, and lost an average of 12.2% body weight in 12 months.

Cohorts differed in inclusion criteria, medication type, and follow-up duration. Not randomized, controlled clinical trials. Self-reported outcomes have not been independently verified. Individual results may vary. 5 Supra note 3. 6 Based on survey

responses of 166 participants in a 6-month clinical trial who had overweight or obesity, and were taking semaglutide/ tirzepatide for weight loss through Weight Watchers Med+ and provided the GLP-1 Success Program. 7 Based on an internal analysis of

data from December 2024 to April 2025 of 3,264 Weight Watchers Med+ members during their first 12 weeks of membership. 6.5% members who had at least 1 RD visit discontinued their treatment plan. 9.3% members who did not have at least 1 RD visit

discontinued their treatment plan. Treatment discontinuation means canceling Weight Watchers Med+ membership or switching medication treatment plans. 8 Based on a 6-month clinical trial (n=180) of individuals who were enrolled between February-April

2024, with overweight or obesity taking semaglutide/tirzepatide for weight loss and related outcomes within Weight Watchers Med+ who increased their Healthy Eating Index score from 55.0 to 65.1. Heinberg et al. Effectiveness of Telemedicine

Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study. Obesity. 2025. Funded by WW International, Inc. 9 Based on a 6-month randomized controlled trial (n=376) that compared participants following WW to

those given standard nutritional guidelines alone where 19.3% of WW participants achieved 10% weight loss. Palacios et al. Effectiveness of a digital weight management program on diet quality: a randomized controlled trial. AJCN. 2025. Funded by WW

International, Inc. 10 Based on a secondary analysis of Palacios et al. 2025, a 6-month randomized controlled trial (n=376 adults) that compared participants following WW to those given standard nutritional guidelines alone. Manuscript in draft.

Funded by WW International, Inc. 11 Based on an internal data analysis of 142 Weight Watchers Med+ Menopause program members who requested a refill of their hormone therapy through Weight Watchers and self reported symptom scores before and after

participation in the program. After an average of 43.6 days, average composite menopause symptom scores decreased from 22.1 to 10.5, out of a possible 40 points. Not a randomized, controlled clinical trial. Selfreported outcomes have not been

independently verified. Individual results may vary. 12 Based on an internal data analysis of 1.7M Core program members who didn’t refer someone compared to 82K Core program members who did, conducted from April 2022-April 2023. 13 Based on

internal surveys conducted between December 2025 and January 2026 across various member services. Ratings of 4.9 out of 5 were reported by 1,908 in-person workshop attendees, 7,773 virtual workshop attendees, 4,790 Customer Care users, 8,420

Registered Dietitian patients, and 6,505 clinician patients. 16

Fresh Start Accounting and Predecessor and Successor Periods In connection with the Company’s emergence from its financial

reorganization process on June 24, 2025, the Company’s second quarter ended June 30, 2025 includes a “Predecessor” period from March 30, 2025 to June 24, 2025, and a “Successor” period from

June 25, 2025 to June 30, 2025. Additionally, the Company qualified for and applied fresh start accounting. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial

statements as of or prior to that date. The Company’s third quarter ended September 30, 2025, fourth quarter ended December 31, 2025, and first quarter ended March 31, 2026 all represent a Successor period. Although GAAP

requires that we report our results for the period from March 30, 2025 through June 24, 2025 (Predecessor) and the period from June 25, 2025 through June 30, 2025 (Successor) separately, management views certain metric and

revenue information for the three months ended June 30, 2025 by combining the results of the applicable Predecessor and Successor periods because management believes such presentation provides the most meaningful comparison of our results to

prior periods. Although the Predecessor and Successor periods are generally not comparable as they are impacted by fresh start accounting, there are no fresh start adjustments affecting revenue and therefore revenue information has been combined in

this letter to provide a meaningful understanding of operating trends, which would be consistent with a pro forma calculation under Article 11 of Regulation S-X. Nevertheless, the combined operating results do not reflect the actual results we would

have achieved absent our emergence from its financial reorganization process and may not be indicative of future results. We cannot adequately benchmark the operating results of the period from June 25, 2025 through June 30, 2025

(Successor) against any of the previous periods reported in our consolidated financial statements without combining it with the period from March 30, 2025 through June 24, 2025 (Predecessor) and do not believe that reviewing the results of

this period in isolation would be useful in identifying trends in or reaching conclusions regarding our overall operating performance. Management believes that the key performance metrics such as Subscription Revenue, Incoming and End of Period

Subscribers and Monthly Subscription Revenue per Average Subscriber for the Successor period when combined with the Predecessor period provides more meaningful comparisons to other periods and are useful in identifying current business trends.

Accordingly, this shareholder letter presents the combined results for these metrics for the three months ended June 30, 2025.

Definitions and Performance Indicators “Behavioral” business refers to providing subscriptions to the Company’s

digital product offerings with the option to add on unlimited access to the Company’s workshops. “Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by Weight Watchers

Clinic combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops. “Revenue”—“Subscription Revenue” consists of the aggregate of:

(a) “Behavioral Subscription Revenue”, the fees associated with subscriptions for our Behavioral offerings; and (b) “Clinical Subscription Revenue”, the fees associated with subscriptions for our Clinical offerings.

In addition, “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. Revenue consists of the aggregate of Subscription Revenue and Other Revenue.

“Incoming Subscribers”—“Subscribers” refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill programs in Company-owned operations. The “Incoming Subscribers” metric reports

Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts our revenue growth and

trends. “End of Period Subscribers”—The “End of Period Subscribers” metric reports Subscribers in Company- owned operations at a given period end. Recruitment and retention are key drivers for this metric. Management

utilizes this metric to monitor changes in the subscriber base which directly impacts our revenue growth and trends. “Monthly Subscription Revenue Per Average Subscriber” (“ARPU”)—The “Monthly Subscription Revenue

Per Average Subscriber” metric reports the monthly fees associated with subscriptions for our offerings divided by the Average Subscriber for our businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each

respective business are calculated as Subscription Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each respective business is the average of

its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the

fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis.

Cautionary Note on Forward Looking Statements This shareholder letter includes “forward-looking statements,” within the

meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives,

initiatives, and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,”

“intend,” “aim” and similar expressions in this shareholder letter to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial

performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: our recent emergence

from bankruptcy, which could adversely affect our business and relationships and subjects us to risks and uncertainties; competition from other weight management and health and wellness industry participants or the development of more effective or

more favorably perceived weight management methods; our failure to continue to retain and grow our subscriber base; our ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market;

our ability to continue to develop new, innovative services and products and enhance our existing services and products or the failure of our services, products or brands to continue to appeal to the market, or our ability to successfully expand

into new channels of distribution or respond to consumer trends or sentiment; our ability to successfully implement strategic initiatives; the effectiveness and efficiency of our advertising and marketing programs, including the strength of our

social media presence; the impact on our reputation of actions taken by our franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners; the recognition of asset impairment charges; the

loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate our workforce; our chief executive officer transition, and our ability to appoint a new chief executive officer with the required level of

experience and expertise in a timely manner; our ability to successfully make acquisitions or enter into collaborations or joint ventures, including our ability to successfully integrate, operate or realize the anticipated benefits of such

businesses; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, changes in tariffs and escalating trade tensions, rising interest rates, the

potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of our business; our failure to maintain effective internal control over financial reporting; the impact of events that

impede accessing resources or discourage or impede people from gathering with others; the early termination by us of leases; the inability to renew certain of our licenses, or the inability to do so on terms that are favorable to us; the dependence

of our payments system on third- party service providers; the impact of our exposure to variable rate indebtedness; the ability to generate sufficient cash to service our debt and satisfy our other liquidity requirements; uncertainties regarding the

satisfactory operation of our technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; our ability to successfully

integrate and use artificial intelligence in our business; our ability to enforce our intellectual property rights both domestically and internationally, as well as the impact of our involvement in any claims related to intellectual property rights;

the impact of existing and future laws and regulations; risks related to our exposure to extensive and complex healthcare laws and regulations; the outcomes of litigation or regulatory actions; risks and uncertainties associated with our

international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; our ability to engage in share repurchases and pay cash

dividends in the foreseeable future; risks related to the actions of activist shareholders and anti-takeover provisions in our articles of incorporation and bylaws; risks related to the actions of our shareholders and the exclusive forum provisions

in our articles of incorporation; the possibility that we could fail to maintain the listing of our common stock on Nasdaq; and other risks and uncertainties, including those included in this shareholder letter and those detailed from time to time

in our periodic reports filed with the Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put

undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any

forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this

shareholder letter or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the

Company’s website at corporate.ww.com).

Reconciliation to GAAP Measures of Non-GAAP Financial Measures To supplement the Company’s

consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results

that exclude or adjust certain items. The Company presents in this letter non-GAAP financial measures, including earnings before interest, taxes, depreciation and amortization expenses and share-based

compensation expense (“EBITDA”); and for each period presented, EBITDA adjusted, as applicable, for (a) goodwill and other intangible assets impairments, (b) reorganization items, net related to the Company’s emergence

from its Chapter 11 financial reorganization, (cl transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization, (d) net restructuring charges associated with the previously disclosed 2025,

2024, and 2023 restructuring plans, (el non-CEO executive separation expenses and (f) other items such as the impact of foreign exchange gains and losses as indicated in the reconciliations below that

management believes are not indicative of ongoing operations (“Adjusted EBITDA”). The Company also presents gross profit, gross margin, marketing expenses, selling, general and administrative expenses, and product development expenses on

a non-GAAP basis that adjusts for similar items, as further indicated in the reconciliations included elsewhere in this shareholder letter. In addition, the Company presents certain of its financial results on

a constant currency basis in addition to GAAP results. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company calculates constant currency by calculating current-year

results using prior-year foreign currency exchange rates. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the

Company’s business performance and are useful for period-over-period comparisons of the performance of the Company’s business. While management believes that these non-GAAP financial measures are

useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with

GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See “Reconciliation to GAAP Measures of

Non-GAAP Financial Measures” in to this shareholder letter and reconciliations, if any, included elsewhere in this shareholder letter for a reconciliation of the

non-GAAP financial measures to the most directly comparable GAAP measures.

Operational Statistics (In Thousands, Except Percentages and Monthly Subscription Revenue Per Average Subscriber) Unaudited Incoming

Subscribers(1) Incoming Behavioral Subscribers 2,631 N/A 3,244 (18.9%) N/A Incoming Clinical Subscribers 130 N/A 92 41.9% N/A End of Period Subscribers(2) End of Period Behavioral Subscribers 2,463 N/A 3,299 (25.4%) N/A End of Period

Clinical Subscribers 197 N/A 135 45.9% N/A Monthly Subscription Revenue Per Average Subscriber(3) Monthly Behavioral Subscription Revenue Per Average Subscriber $ 16.82 $ 16.27 $ 15.87 6.0% 2.6% Monthly Clinical Subscription Revenue Per Average

Subscriber $ 79.23 $ 79.23 $ 86.70 (8.6%) (8.6%) Note: Totals may not sum due to rounding. (1) The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start. (2) The

“End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end. (3) The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with

subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of

months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period.

Revenue—Constant Currency (In Thousands, Except Percentages); Unaudited Behavioral Subscription Revenue(2) $ 128,524 $ 124,317 $ 15 5,723 (17.5%) (20.2%) Clinical Subscription Revenue(3) $ 38,833 $ 38,833 $ 29,457 31.8% 31.8%

Subscription Revenue’41 $ 167,357 $ 163,150 $ 185,180 (9.6%) (11.9%) Other Revenue(5) $ 904 $ 858 $ 1,391 (35.0%) (38.3%) Note: Totals may not sum due to rounding. Note: Totals may not sum due to rounding.

(1) “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue. (2) “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral

offerings. (3) “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings. (4) “Subscription Revenue” is the sum of Behavioral Subscription Revenue

and Clinical Subscription Revenue. (5) “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

Net (Loss) Income to Adjusted EBITDA (In Thousands, Except Percentages); Unaudited Interest 11,475 11,767 12,052 923 11,061 27,603 Taxes

10,823 (18,856) 53,157 (523) (20,906) 22,575 Behavioral $129M $156M Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K Note: Totals may not sum due to rounding. (1) The Company’s franchise rights acquired impairment

charge related to its United States unit of account. (2) The net reorganization gain related to the Company’s emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject

to compromise and the impacts of fresh start valuation adjustments. (3) Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization. (4) Restructuring charges

previously disclosed 2023 restructuring plan. (5) Certain non-recurring expenses in connection with the separation from the Company of a non-Chief Executive Officer executive. (6) Primarily consists of the impact of foreign exchange gains

and losses.

Gross Profit, Marketing Expenses, Selling, General & Administrative (SG&A), Product Development Expenses (In Thousands,

Except Percentages); Unaudited % of Revenue 70.5% 55.2% 4.8% 28.6% 71.2% 42.2% 6.0% 19.1% Adjustments: Transaction Costs(1) (10,823) Depreciation and Amortization Expenses 5,180 (20,706) 4,500 (61) (2,354) Restructuring Charges

(2) (65) — (533) (384) — (1,356) Share-based Compensation Expense 0 (141) (109) (436) (860) Non-CEO Executive Separation Expenses(3) (1,563) Total Adjustments $ 5,115 $ (141) $

(109) $ (2 3,238) $ 4,116 $—$ (61) $ (15,394) % of Revenue 73.6% 55.1% 4.7% 14.8% 73.4% 42.2% 5.9% 10.8% Currency Adjustment (3,690) (959)—(301) N/A N/A N/A N/A % of Revenue 70.1% 56.1% 4.9% 29.1% N/A N/A N/A N/A

% of Revenue 73.2% 56.0% 4.9% 15.0% N/A N/A N/A N/A Note: Totals may not sum due to rounding. (1) Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

(2) Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, 2024 restructuring plan,

and 2023 restructuring plan. (3) Certain non-recurring expenses in connection with the separation from the Company of a non-Chief Executive Officer executive. % of Revenue 70.1% 40.2% 5.4% 32.4% 72.1% 28.1% 4.4% 34.9% 73.2% 22.9% 5.6% 23.4%

73.7% 18.1% 8.0% 24.2% Adjustments: Transaction Costs (1) ——514 ——(9,126) ——(182) ——(10,049) Depreciation and Amortization Expenses

5,350—(59) (20,899) 5,135—(58) (20,301) 330—(4) (1,347) 4,147—(54) (3,086) Restructuring Charges (2) 1,618 — (2,966) 23 — (99) — —

(2,071) — (977) Share-based Compensation Expense (604) (3,173) Total Adjustments $ 6,968 $—$ (59) $ (23,955) $ 5,158 $—$ (58) $ (29,525) $ 330 $—$ (4) $ (1,529) $ 2,076

$—$ (54) $ (17,285) % of Revenue 74.4% 40.2% 5.4% 17.6% 75.1% 28.1% 4.4% 17.8% 75.9% 22.9% 5.6% 10.9% 74.9% 18.1% 8.0% 14.4% Note: Totals may not sum due to rounding. (1) Certain non-recurring transaction costs related to

strategic alternatives and the Company’s Chapter 11 financial reorganization. (2) Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges

include the previously disclosed 2025 restructuring plan, 2024 restructuring plan, and 2023 restructuring plan.

Consolidated Balance Sheets (In Thousands); Unaudited ASSETS CURRENT ASSETS Cash and cash equivalents $ 120,870 $ 160,279 Behavioral

$129M $156M Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K Goodwill 200,000 200,135 Other intangible assets, net 471,528 490,664 Deferred income taxes 16,254 16,482 Other noncurrent assets 14,910 14,825 TOTAL ASSETS $ 881,071 $ 946,758

LIABILITIES AND EQUITY CURRENT LIABILITIES Behavioral $129M $156M Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K TOTAL LIABILITIES 615,500 628,687 EQUITY Successor common stock, $0 par value; 1,000,000 shares authorized; 9.996 shares

issued at March 31, 2026 and 9,992 shares issued at December 31, 2025 379,306 378,777 Accumulated deficit (114,095) (62,095) Accumulated other comprehensive income 360 1,389 TOTAL EQUITY 265,571 318,071 TOTAL LIABILITIES AND

TOTAL EQUITY $ 881,071 $ 946,758

Consolidated Statement of Operations (In Thousands, Except Per Share Amounts); Unaudited Subscription revenue, net (1) $ 167,357 $

185,180 Other revenue, net (2) 904 1,391 Revenue, net 168,261 186,571 (3) Cost of subscription revenue 49,445 53,587 Cost of other revenue 144 108 Cost of revenue 49,589 53,695 Gross profit 118,672 132,876 Marketing expenses 92,934 78,778

Product development expenses 8,093 11,121 Selling, general and administrative expenses 48,084 35,629 Franchise rights acquired impairments 27,549 Operating loss (30,439) (20,201) Interest expense 11,475 27,60 3 Other (income) expense, net

(737) 2,206 Loss before income taxes (41,177) (50,010) Provision for income taxes 10,823 22,575 Net loss $(52,000) $(72,585) Net loss per share Basic $(5.20) $(0.91) Diluted $ (5.20) $(0.91) Weighted average common shares

outstanding Basic 9,996 80,129 Diluted 9,996 80,129 Note: Totals may not sum due to rounding. (1) “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees

associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. (2) “Other

revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. (3) “Cost of subscription revenue” consists of cost of revenue and operating

expenses for the Company’s Behavioral and Clinical services.

Consolidated Statements of Cash Flows (In Thousands); Unaudited Operating activities: Net (loss) income $ (52,000) $

(72,585) Behavioral $129M $156M Clinical $39M $29M Behavioral 2.5M 3.3M Clinical 197K 135K Capitalized software and website development expenditures (5,797) (3,170) Cash used for investing activities

(5,797) (3,175) Financing activities: Borrowings on revolving credit facility 171,341 Taxes paid related to net share settlement of equity awards (93) Cash provided by (used for) financing activities 171,248 Effect of exchange rate

changes on cash and cash equivalents and restricted cash (566) 1,529 Net increase (decrease) in cash and cash equivalents and restricted cash (39,910) 184,600 Cash and cash equivalents and restricted cash, beginning of period 166,577

56,520 Cash and cash equivalents and restricted cash, end of period $ 126,667 $ 241,120

Contact Information Investors Media John Mills or Anna Kate Heller Lizzy Levitan WeightWatchers@icrinc.com WW@hunt-gather.com

GRAPHIC

Filename: g116881dsp017.jpg · Sequence: 8

Binary file (344691 bytes)

Download g116881dsp017.jpg

GRAPHIC

Filename: g116881dsp018.jpg · Sequence: 9

Binary file (510827 bytes)

Download g116881dsp018.jpg

GRAPHIC

Filename: g116881dsp019.jpg · Sequence: 10

Binary file (370443 bytes)

Download g116881dsp019.jpg

GRAPHIC

Filename: g116881dsp020.jpg · Sequence: 11

Binary file (350325 bytes)

Download g116881dsp020.jpg

GRAPHIC

Filename: g116881dsp021.jpg · Sequence: 12

Binary file (232540 bytes)

Download g116881dsp021.jpg

GRAPHIC

Filename: g116881dsp022.jpg · Sequence: 13

Binary file (242478 bytes)

Download g116881dsp022.jpg

GRAPHIC

Filename: g116881dsp023.jpg · Sequence: 14

Binary file (337637 bytes)

Download g116881dsp023.jpg

GRAPHIC

Filename: g116881dsp024.jpg · Sequence: 15

Binary file (405002 bytes)

Download g116881dsp024.jpg

GRAPHIC

Filename: g116881dsp025.jpg · Sequence: 16

Binary file (318246 bytes)

Download g116881dsp025.jpg

GRAPHIC

Filename: g116881dsp026.jpg · Sequence: 17

Binary file (256083 bytes)

Download g116881dsp026.jpg

GRAPHIC

Filename: g116881dsp027.jpg · Sequence: 18

Binary file (215336 bytes)

Download g116881dsp027.jpg

GRAPHIC

Filename: g116881dsp028.jpg · Sequence: 19

Binary file (208832 bytes)

Download g116881dsp028.jpg

GRAPHIC

Filename: g116881dsp029.jpg · Sequence: 20

Binary file (320281 bytes)

Download g116881dsp029.jpg

GRAPHIC

Filename: g116881dsp030.jpg · Sequence: 21

Binary file (291129 bytes)

Download g116881dsp030.jpg

GRAPHIC

Filename: g116881dsp031.jpg · Sequence: 22

Binary file (341739 bytes)

Download g116881dsp031.jpg

GRAPHIC

Filename: g116881dsp032.jpg · Sequence: 23

Binary file (488191 bytes)

Download g116881dsp032.jpg

GRAPHIC

Filename: g116881dsp033.jpg · Sequence: 24

Binary file (425453 bytes)

Download g116881dsp033.jpg

GRAPHIC

Filename: g116881dsp034.jpg · Sequence: 25

Binary file (327530 bytes)

Download g116881dsp034.jpg

GRAPHIC

Filename: g116881dsp035.jpg · Sequence: 26

Binary file (295517 bytes)

Download g116881dsp035.jpg

GRAPHIC

Filename: g116881dsp036.jpg · Sequence: 27

Binary file (391303 bytes)

Download g116881dsp036.jpg

GRAPHIC

Filename: g116881dsp037.jpg · Sequence: 28

Binary file (272917 bytes)

Download g116881dsp037.jpg

GRAPHIC

Filename: g116881dsp038.jpg · Sequence: 29

Binary file (263441 bytes)

Download g116881dsp038.jpg

GRAPHIC

Filename: g116881dsp039.jpg · Sequence: 30

Binary file (184615 bytes)

Download g116881dsp039.jpg

GRAPHIC

Filename: g116881dsp040.jpg · Sequence: 31

Binary file (291787 bytes)

Download g116881dsp040.jpg

GRAPHIC

Filename: g116881dsp041.jpg · Sequence: 32

Binary file (168182 bytes)

Download g116881dsp041.jpg

GRAPHIC

Filename: g116881dsp042.jpg · Sequence: 33

Binary file (172236 bytes)

Download g116881dsp042.jpg

GRAPHIC

Filename: g116881dsp043.jpg · Sequence: 34

Binary file (156065 bytes)

Download g116881dsp043.jpg

GRAPHIC

Filename: g116881dsp044.jpg · Sequence: 35

Binary file (423704 bytes)

Download g116881dsp044.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 37

v3.26.1

Document and Entity Information

May 07, 2026

Document And Entity Information [Line Items]

Amendment Flag

false

Entity Central Index Key

0000105319

Document Type

8-K

Document Period End Date

May 07, 2026

Entity Registrant Name

WW INTERNATIONAL, INC.

Entity File Number

001-16769

Entity Tax Identification Number

11-6040273

Entity Address, Address Line One

18 West 18th Street

Entity Address, Address Line Two

7th Floor

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Postal Zip Code

10011

City Area Code

(212)

Local Phone Number

589-2700

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, no par value

Trading Symbol

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Document And Entity Information [Line Items]

Entity Incorporation State Country Code

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- References

No definition available.

+ Details

Name:

ww_DocumentAndEntityInformationLineItems

Namespace Prefix:

ww_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Details

Name:

srt_StatementGeographicalAxis=stpr_VA

Namespace Prefix:

Data Type:

Balance Type:

Period Type: